natural remedies · Ingredient
Berberime
Formula: C20H18NO4+ · MW: 336.3670000000001 · Drug-likeness: 0.674
⚗️ Identity
Name
Berberime
Aliases / Synonyms
berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium
🧪 Chemistry
Molecular Weight
336.3670
LogP
3.0963
Drug-likeness
0.674
H-Bond Acceptors
4
Rotatable Bonds
2
🔗 External References
37
Clinical Trials
53
Meta-Analyses
38
PubMed References
Top Conditions Studied with Berberime
Gastritis|Peptic Ulcer|Dyspepsia 2
Diabetes Mellitus 2
Type 2 diabetes.Chronic metabolic diseases. 1
Diabetic nephropathy (DN), or diabetic kidney disease (DKD), 1
Glycemia 1
Over the past decades, the efficacy and safety of berberine 1
Type 2 Diabetes 1
Cardiovascular Risk Factor 1
Helicobacter pylori (Hp) ：Isolated from patients with chroni 1
Nonalcoholic Fatty Liver Disease 1
Type 2 diabetes mellitus (T2DM) is one of the most common ch 1
Chronic Steatosis disease is a common cause of liver-related 1
📋 Sample Trials
NCT00425009
Therapeutic Effects of Berberine in Patients With Type 2 Diabetes
Completed · Phase 1|Phase 2 · Type 2 Diabetes
NCT00462046
Efficacy and Safety of Berberine in the Treatment of Diabetes With Dyslipidemia
Completed · Phase 3 · Diabetes Mellitus, Type 2|Metabolic Synd
NCT00633282
Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease
Completed · Phase 2 · Nonalcoholic Fatty Liver Disease
NCT02078167
Long Term Efficacy and Tolerability of a Nutraceutical Combination (Red Yeast Rice, Policosanols and Berberine) in Low-moderate Risk Hypercholesterolemic Patients: a Double-blind, Placebo Controlled Study
Completed · Phase 4 · Hypercholesterolemia
NCT02296021
Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy
Completed · Phase 4 · Gastritis|Peptic Ulcer|Dyspepsia
NCT02633930
Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Clarithromycin Quadruple Therapy
Completed · Phase 4 · Gastritis|Peptic Ulcer|Dyspepsia
📊 Sample Meta-Analyses
CRD42011001335
Efficacy and safety of adding berberine to oral hypoglycaemia agents in lowering blood glucose among adults with type 2 diabetes mellitus: a systematic review
The prevalence of diabetes mellitus in the USA and China indicates that it has b
CRD42016044031
Berberine for polycystic ovary syndrome: a systematic review and meta-analysis of randomization controlled trials
Polycystic ovary syndrome. Berberine for Polycystic ovary syndrome.
CRD42018088497
Effectiveness of berberine for patients with acute coronary syndrome
Berberine Berberine for patients with acute coronary syndrome
CRD42018094421
The efficacy and safety of berberine for dyslipidaemias: a systematic review and meta-analysis of randomized clinical trials
Dyslipidaemias, characterized by increased plasma levels of total cholesterol (T
CRD42019123225
Efficacy and safety of berberine in the treatment of type 2 diabetes with insulin resistance: a systematic review and meta-analysis
There are many patients with type 2 diabetes and insulin resistance. The use of
CRD42019142286
Effect of berberine for experimental chemical and drug induced liver injury: a systematic review and meta-analysis
📚 Sample References
PMID 34826601
The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition
Pharmacol Res · 2021
PMID 34890544
Berberine inhibits pancreatic intraepithelial neoplasia by inhibiting glycolysis via the adenosine monophosphate -activated protein kinase pathway
Eur J Pharmacol · 2021
PMID 34923903
Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study
Gut Microbes · 2021
PMID 34968467
Berberine inhibits gastric cancer development and progression by regulating the JAK2/STAT3 pathway and downregulating IL-6
Life Sci · 2021
PMID 34984827
Berberine ameliorates aGVHD by gut microbiota remodelling, TLR4 signalling suppression and colonic barrier repairment for NLRP3 inflammasome inhibition
J Cell Mol Med · 2022
PMID 35001506
Berberine regulates mesangial cell proliferation and cell cycle to attenuate diabetic nephropathy through the PI3K/Akt/AS160/GLUT1 signalling pathway
J Cell Mol Med · 2022
🏥 Linked Health Topics 7 · matched via study conditions